Welcome to our dedicated page for Stevanato Group S P A SEC filings (Ticker: STVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Stevanato Group S.p.A. (NYSE: STVN) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including interim reports on Form 6-K and related exhibits. As a foreign private issuer, Stevanato Group uses Form 6-K to furnish unaudited interim condensed consolidated financial statements, management discussion and analysis, conference call scripts, and investor presentations.
In these filings, investors can review detailed revenue and margin information by segment for the Biopharmaceutical and Diagnostic Solutions and Engineering businesses, along with data on cost of sales, operating profit, finance income and expense, income taxes, and net profit. The interim reports also present information on property, plant and equipment, capital expenditures, cash flows, and net debt, helping readers understand the company’s investment and financing profile.
Stevanato Group’s 6-K filings include cautionary statements regarding forward-looking information and extensive risk factor discussions. These sections address topics such as product quality, technological change, competition, supply chain conditions, tariffs, geopolitical events, regulatory requirements, intellectual property, cybersecurity, and internal controls. The company also explains its use of non-GAAP measures, including EBITDA, Adjusted EBITDA, Adjusted Operating Profit, Adjusted Net Profit, Adjusted Diluted EPS, CAPEX, Free Cash Flow, Net Cash/(Debt), and Capital Employed, and provides reconciliations in accompanying materials.
Through this page, users can follow real-time updates from EDGAR as new Stevanato Group filings are posted, including earnings-related 6-Ks, conference call scripts, and investor presentations. Stock Titan’s AI-powered tools summarize key points from lengthy documents, highlight important trends in revenue, margins, and capital investments, and make it easier to interpret complex tables and disclosures.
For those researching STVN, this filings archive offers a structured view of Stevanato Group’s financial reporting, risk disclosures, and strategic commentary, directly sourced from its official SEC submissions.
Stevanato Group reported solid fourth quarter and full-year 2025 growth, driven by high-value biopharmaceutical packaging and delivery solutions. For 2025, revenue rose 9% at constant currency and 7% on a reported basis, with the Biopharmaceutical and Diagnostic Solutions segment delivering double-digit growth that offset an expected decline in Engineering.
High-value solutions grew 29% in 2025 and accounted for 46% of total revenue, helping expand gross margin by 160 basis points versus 2024. In Q4 2025, revenue reached €346.5 million, up 7% at constant currency and 5% reported, with high-value solutions up 31% to €171 million, or 49% of sales, and gross margin improving to 30.9%, up 120 basis points.
Management guided 2026 revenue to €1.73–€1.76 billion, adjusted EBITDA of €331.8–€346.9 million and adjusted diluted EPS of €0.59–€0.63, with foreign exchange expected to be an €18 million headwind. High-value solutions are expected to contribute 47–48% of 2026 revenue, supported by GLP-1-related products, biologics programs and ramping capacity at Latina and Fishers. Capital expenditures are planned at €270–€290 million gross (or €240–€260 million net of customer contributions), with 2026 free cash flow modeled between breakeven and about €20 million.
Stevanato Group S.p.A. presents its annual report describing its role as a global provider of drug containment, drug delivery and diagnostic solutions and specialized manufacturing lines for pharma, biotech and life sciences customers.
The company reports authorized share capital of €22,231,562.00 divided into 302,842,536 shares without par value. As of December 31, 2025, this total included 49,709,718 ordinary shares and 253,132,818 Class A shares.
In March 2024 Stevanato completed an upsized follow-on public offering of 14,605,000 ordinary shares at a public price of $26.00 per share, and in October 2023 its board was delegated authority to increase share capital in cash by up to €350,000,000 within a 10% limit of currently outstanding shares.
The report highlights a backlog of about €871 million at December 31, 2025, modestly higher than €853 million a year earlier, and details a growth strategy focused on expanding high-value ready-to-use primary packaging, drug delivery systems, life sciences equipment and global manufacturing capacity, particularly in the United States and Italy.
Extensive risk disclosures emphasize product quality and recall exposure, dependence on key customers and employees, supply chain and energy-cost pressures, geopolitical and macroeconomic uncertainty, regulatory and tax complexity, information technology and cybersecurity threats, and the implications of dual-class share structure, potential future dilution and obligations as a foreign private issuer listed on the New York Stock Exchange.
Stevanato Group reported solid Q4 and full-year 2025 performance driven by high-value solutions. For 2025, total revenue grew 9% at constant currency (7% reported), with High-Value Solutions (HVS) up 29% year over year as the main driver of margin expansion.
In Q4 2025, revenue rose to €346 million from €331 million, with gross profit margin improving 120 bps to 30.9%. Adjusted EBITDA increased 7% to €97 million, for a 28.2% margin. Net profit was €47 million, or €0.17 diluted EPS, and adjusted net profit was €49 million, or €0.18 adjusted diluted EPS.
The Biopharmaceutical and Diagnostic Solutions segment grew Q4 revenue 10% to €307 million, while the Engineering segment declined 23% to €39.4 million as optimization efforts continued. HVS revenue reached €171.4 million in Q4, up 31% and representing 49% of total revenue, supported by strong demand for Nexa prefilled syringes and GLP1-related products.
For 2025, cash from operating activities was €286.1 million, free cash flow was €18.4 million after €294.9 million of capex, and net debt stood at €337.7 million with €130.6 million of cash at year-end. Management guided 2026 revenue to €1.260–€1.290 billion, adjusted EBITDA to €331–€346 million, and adjusted diluted EPS to €0.59–€0.63, expecting HVS to account for about 47–48% of revenue and capital expenditures of €270–€290 million. The company also disclosed that internal control over financial reporting was not effective for the year ended December 31, 2025.
Stevanato Group reported solid growth for fiscal 2025, with revenue up 7% to €1.186 billion and high-value solutions reaching 46% of sales. Gross profit margin improved to 29.0%, adjusted EBITDA rose to €298.0 million with a 25.1% margin, and diluted EPS increased 19% to €0.51, while adjusted diluted EPS reached €0.54. The Biopharmaceutical and Diagnostic Solutions segment grew 10% in the fourth quarter to €307.1 million, and GLP1-related products represented roughly 19% to 20% of full-year revenue. Free cash flow turned positive at €18.4 million despite €294.9 million of CAPEX, and net debt stood at €337.7 million. For 2026, the company guides revenue to €1.26–€1.29 billion, adjusted EBITDA to €331.8–€346.9 million, and adjusted diluted EPS to €0.59–€0.63, signaling expectations for continued growth and margin expansion.
Artisan Partners, through several affiliated Delaware entities, reports beneficial ownership of 2,349,842 ordinary shares of Stevanato Group S.p.A., representing 4.7% of the share class based on 49,604,649 shares outstanding as of 3/31/2025.
The group has shared voting power over 1,916,301 shares and shared dispositive power over all 2,349,842 shares, with no sole voting or dispositive authority. The filing states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Stevanato.
Conestoga Capital Advisors has reported a significant ownership position in Stevanato Group S.p.A. common stock as of 12/31/2024. Conestoga Capital Advisors beneficially owns 8,322,390 shares, representing 16.74% of the outstanding common stock, with sole voting power over 7,889,700 shares and sole dispositive power over 8,322,390 shares.
CONESTOGA FUNDS, a related Delaware entity, beneficially owns 4,423,906 shares of Stevanato Group common stock, equal to 8.9% of the class, with sole voting and dispositive power over all of those shares. The filing states that these securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Stevanato Group.
Neuberger Berman Group LLC and related entities report passive ownership of common shares of Stevanato Group S.p.A. under a Schedule 13G/A. Neuberger Berman Group LLC reports beneficial ownership of 4,960,362 shares, representing 10.0% of Stevanato’s common stock, with shared voting power over 4,725,907 shares and shared dispositive power over the full 4,960,362 shares as of the event date. Neuberger Berman Investment Advisers LLC reports beneficial ownership of 4,806,300 shares, or 9.7% of the class, with shared voting and dispositive powers over those shares.
The filing explains that these shares are held across various client and fiduciary accounts, and Neuberger Berman entities disclaim economic ownership, noting that clients retain the right to dividends and sale proceeds. The certification states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Stevanato Group.
Stevanato Group S.p.A. reported unaudited Q3 and nine‑month 2025 results showing higher sales and profitability. Q3 revenue was €303.2 million (up from €277.9 million), with operating profit of €52.7 million and net profit of €36.1 million; basic EPS was €0.13 (vs €0.11). Nine‑month revenue reached €839.8 million (vs €773.4 million), operating profit €128.7 million, and net profit €92.3 million.
Growth was led by the Biopharmaceutical and Diagnostic Solutions segment (Q3 €266.7 million), including a step‑up in high‑value solutions (€147.9 million vs €100.4 million). The Engineering segment posted €36.4 million. Cash from operations strengthened to €192.0 million year‑to‑date, while capex of €187.7 million supported the ramp‑up of the Fishers (U.S.) and Latina (Italy) sites. The company entered a rent‑to‑buy agreement for its Zhangjiagang, China facility and reported cash of €113.3 million at period end.
The effective tax rate improved to 25.2% for the nine months, reflecting Italy’s one‑year “IRES premiale” benefit. Net foreign exchange effects were a loss of €14.0 million year‑to‑date. One customer represented 12.6% of nine‑month revenue.